{"release_id":19,"data":{"id":92733,"release_id":19,"source_id":"sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026","kind":"topic","fingerprint":"12090f540e9f90ad14cbcdc7b79bc4d5075a908c5efcedf23b4546015ce738ff","title_en":"HSA Post-marketing Vigilance Guidance 2026","title_zh":"HSA \u4e0a\u5e02\u540e\u76d1\u6d4b\u6307\u5357 2026 \u5e74","domain":"healthcare","status":null,"assurance":null,"subtype":null,"lat":null,"lon":null,"date":null,"payload":{"bundle_sha256":"45bf7e4a6e04877a9385caa9d5613e31f964959fced55c1117ce10170e4f73ce","checks":{"translation":"passed"},"data":{"aliases":["HSA post-marketing vigilance","therapeutic product adverse-event reporting Singapore","CTGTP vigilance guidance"],"answer_profile":"mixed","description":"HSA\u2019s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.","id":"sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026","label":"HSA Post-marketing Vigilance Guidance 2026","parent_id":"sgtopic.healthcare","primary_domain":"healthcare"},"date":null,"domain":"healthcare","evidence_paths":["source\/taxonomy\/topics.jsonl","artefacts\/knowledge-records.jsonl"],"kind":"topic","links":[{"relation":"parent_id","target_id":"sgtopic.healthcare"}],"source_id":"sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026","status":null,"summary_en":"HSA\u2019s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.","summary_zh":"\u536b\u751f\u79d1\u5b66\u5c40\u7684 2026 \u5e74\u4e0a\u5e02\u540e\u8b66\u6212\u6307\u5357\u9610\u660e\u6cbb\u7597\u4ea7\u54c1\u7684\u5b89\u5168\u62a5\u544a\u804c\u8d23\u548c\u63d0\u4ea4\u8981\u6c42\u3002","title_en":"HSA Post-marketing Vigilance Guidance 2026","title_zh":"HSA \u4e0a\u5e02\u540e\u76d1\u6d4b\u6307\u5357 2026 \u5e74","translation_work":[{"field":"title_zh","fingerprint":"110fd4e8fbfc30f266ca8ff87cdbb3a5ebad1600a86c1256a9e26fbd0d3e2267","source_en":"HSA Post-marketing Vigilance Guidance 2026","status":"reused"},{"field":"summary_zh","fingerprint":"48ad0294107fb216a6af55247ac1f6e78ba13609deef8bf14dfc014a9fff95ce","source_en":"HSA\u2019s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.","status":"reused"}]},"search_text":"HSA Post-marketing Vigilance Guidance 2026\nHSA \u4e0a\u5e02\u540e\u76d1\u6d4b\u6307\u5357 2026 \u5e74\nHSA\u2019s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.\n\u536b\u751f\u79d1\u5b66\u5c40\u7684 2026 \u5e74\u4e0a\u5e02\u540e\u8b66\u6212\u6307\u5357\u9610\u660e\u6cbb\u7597\u4ea7\u54c1\u7684\u5b89\u5168\u62a5\u544a\u804c\u8d23\u548c\u63d0\u4ea4\u8981\u6c42\u3002\n{\"aliases\":[\"HSA post-marketing vigilance\",\"therapeutic product adverse-event reporting Singapore\",\"CTGTP vigilance guidance\"],\"answer_profile\":\"mixed\",\"description\":\"HSA\u2019s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.\",\"id\":\"sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026\",\"label\":\"HSA Post-marketing Vigilance Guidance 2026\",\"parent_id\":\"sgtopic.healthcare\",\"primary_domain\":\"healthcare\"}\n"},"related":[{"id":90524,"source_id":"sgkb.healthcare.hsa-post-marketing-vigilance-guidance-2026","kind":"article","title_en":"HSA Post-marketing Vigilance Guidance 2026","title_zh":"HSA \u4e0a\u5e02\u540e\u8b66\u6212\u6307\u5357 2026","assurance":null,"subtype":null},{"id":80398,"source_id":"sg.guidance.hsa-post-marketing-vigilance-v6","kind":"entity","title_en":"HSA Post-marketing Vigilance Guidance Version 6","title_zh":"HSA \u4e0a\u5e02\u540e\u76d1\u6d4b\u6307\u5357\u7b2c 6 \u7248","assurance":null,"subtype":"post-marketing-safety-surveillance-guidance"},{"id":91573,"source_id":"sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision","kind":"observation","title_en":"HSA post-marketing vigilance guidance Version 6","title_zh":"HSA\u4e0a\u5e02\u540e\u8b66\u6212\u6307\u5357\u7b2c 6 \u7248","assurance":null,"subtype":null},{"id":92737,"source_id":"sgtopic.healthcare","kind":"topic","title_en":"Healthcare","title_zh":"\u533b\u7597\u4fdd\u5065","assurance":null,"subtype":null}]}